According to Roche, the HER2 (4B5) clone consistently achieves high proficiency assessment scores against other clones. "FDA ...

In the near future, oncologists should be able to identify and manage cardiac risks, both in clinical trials and daily practice. Many successful agents – including anthracyclines and trastuzumab ...

Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.

Roche (RHHBY) announced that the U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) ...

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed ...

US FDA approves Roche’s companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with Ziihera: Tucson, Arizona Tuesday, November ...

The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.